This article was originally published in Start Up
Executive SummaryIt's rare to find a drug development start-up that has grown to more than 50 people and raised over $100 million before putting its first molecule into the clinic. That's the history of CovX, which uses a humanized antibody as a scaffold for developing multiple drugs with the desirable properties of both the antibody and specific peptides or small molecules that are linked to it.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.
Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.
No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.